Researchers from the Kingdom of Bahrain recently compared two leading biologic therapies for treating severe asthma to determine which provided the better outcome. According to the study, “A Prospective Observational Study Evaluating the Efficacy of Omalizumab and Mepolizumab in Patients With Severe Asthma,” both appeared to have meaningful strengths in different areas of importance. The study was recently published in the Cureus Journal of Medical Science.
Biologic therapies like omalizumab (anti-IgE) and mepolizumab (anti-IL-5) offer new options for treating severe asthma, but real-world comparative data are limited. In the observational study conducted at Bahrain’s Salmaniya Medical Complex, researchers followed 72 patients over a 12-month period. They found that both treatments significantly improved asthma control with notable differences in outcomes. Mepolizumab correlated with better asthma control, while omalizumab patients reported better quality of life.
Key findings from the study include:
- Asthma control: Overall, 69.4% of patients achieved well-controlled asthma; the omalizumab group had a higher proportion (80%) versus mepolizumab (56.3%).
- Adjusted analysis: Mepolizumab showed a stronger independent association with high asthma control (OR 8.95, p=0.007).
- Combination therapy: Triple inhaler therapy — which combines inhaled corticosteroid, a long-acting beta2-agonist and a long-acting muscarinic antagonist (ICS/LABA/LAMA) — was strongly linked to improved control (OR 32.5).
- Quality of life: Overall, omalizumab ranked higher (70%) versus mepolizumab (46.9%).
- Safety: Both drugs were well tolerated with no major safety concerns reported.
Researchers noted that treatment decisions should be personalized, considering patient characteristics and therapeutic goals. Additionally, they noted that this research is particularly significant for Middle Eastern health care systems, where cost and resource allocation remain critical factors in managing severe asthma.
